相关实验视频
Updated: Jun 26, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
针对突变p53-Y220C的抗癌治疗策略
Vitaly Chasov1, Damir Davletshin1, Elvina Gilyazova1
1Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.
研究人员正在探索通过向突变的p53蛋白 (Y220C) 来对抗癌症的新方法. 小分子和免疫疗法在重新激活这种瘤抑制剂和消除癌细胞方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 蛋白质p53是一种关键的瘤抑制剂,但它的基因 (TP53) 在癌症中经常发生突变.
- 突变的p53蛋白质获得致癌功能,促进癌症的进展和抵抗力.
- 在p53中的Y220C突变产生了具有独特腔的不稳定蛋白质.
研究的目的:
- 审查针对致癌性p53 Y220C突变的治疗策略.
- 探索小分子和免疫疗法在癌症治疗中的潜力.
主要方法:
- 关于p53 Y220C向策略的研究文献综述.
- 对稳定Y220C突变的小分子方法的分析.
- 检查针对p53 Y220C新抗原的免疫治疗策略.
主要成果:
- 小分子可以结合Y220C腔,稳定突变的p53蛋白.
- 重新激活p53 Y220C的野生类型功能是一个可行的治疗目标.
- 针对p53 Y220C新抗原的免疫疗法是未来的方向.
结论:
- 准p53 Y220C突变为癌症治疗提供了一个有希望的途径.
- 小分子稳定和免疫治疗是重新激活突变p53.3的关键策略.
更多相关视频
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mitogens and the Cell Cycle